Analyzing CVRx (NASDAQ:CVRX) & Sigyn Therapeutics (OTCMKTS:SIGY)

CVRx (NASDAQ:CVRX) and Sigyn Therapeutics (OTCMKTS:SIGY) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, risk, institutional ownership, dividends, profitability, analyst recommendations and earnings.

Profitability

This table compares CVRx and Sigyn Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
CVRx	-123.58%	-66.05%	-46.99%
Sigyn Therapeutics	N/A	N/A	-1,022.38%

Earnings & Valuation

This table compares CVRx and Sigyn Therapeutics’ revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CVRx	$39.29 million	6.48	-$41.20 million	($2.47)	-4.77
Sigyn Therapeutics	N/A	N/A	-$4.15 million	N/A	N/A

Sigyn Therapeutics has lower revenue, but higher earnings than CVRx.

Risk and Volatility

CVRx has a beta of 1.26, meaning that its share price is 26% more volatile than the S&P 500. Comparatively, Sigyn Therapeutics has a beta of -1.66, meaning that its share price is 266% less volatile than the S&P 500.

Institutional and Insider Ownership

75.3% of CVRx shares are held by institutional investors. Comparatively, 10.0% of Sigyn Therapeutics shares are held by institutional investors. 18.9% of CVRx shares are held by insiders. Comparatively, 78.5% of Sigyn Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Analyst Recommendations

This is a summary of current recommendations and price targets for CVRx and Sigyn Therapeutics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CVRx	0	2	4	0	2.67
Sigyn Therapeutics	0	0	0	0	N/A

CVRx currently has a consensus price target of $16.60, suggesting a potential upside of 40.92%. Given CVRx’s higher probable upside, research analysts clearly believe CVRx is more favorable than Sigyn Therapeutics.

Summary

CVRx beats Sigyn Therapeutics on 6 of the 10 factors compared between the two stocks.

About CVRx

CVRx, Inc., a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. The company offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure with reduced ejection fraction or systolic heart failure. It sells its products through direct sales force, as well as sales agents and independent distributors in the United States, Germany, and internationally. The company was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.

About Sigyn Therapeutics

Sigyn Therapeutics, Inc., a development-stage company, provides therapeutic solutions in the United States. Its lead product candidate is Sigyn Therapy, a broad-spectrum blood purification technology designed to treat pathogen-associated inflammatory disorders, including endotoxemia and inflammation in end-stage renal disease patients, sepsis, community acquired pneumonia, drug resistant bacterial infections, and emerging pandemic threats. The company is also involved in evaluating the Sigyn Therapy to address various therapeutic targets, including endotoxin; peptidoglycan and lipoteichoic acid; viral pathogens; hepatic toxins; and tumor necrosis factor alpha, interleukin-1 beta, and interleukin 6, which are pro-inflammatory cytokines. In addition, it develops ChemoPrep to enhance the tumor site delivery of chemotherapy; ChemoPure to reduce treatment toxicity and inhibit the spread of cancer metastasis; and ImmunePrep to enhance the potential efficacy of immunotherapeutic antibodies. Sigyn Therapeutics, Inc. was founded in 2019 and is headquartered in San Diego, California.